Effects of magnesium on polymorphic ventricular tachycardias induced by aconitine.
We examined the effects of Mg2+ on aconitine-induced polymorphic ventricular tachycardias (PVT) in excised rabbit hearts under Langendorff perfusion and in Purkinje-muscle preparations. Local electrograms using bipolar electrodes and transmembrane potentials with the microelectrode technique were recorded from Langendorff hearts and Purkinje-muscle preparations, respectively. In Langendorff preparations, intracoronary application of 0.1 microM aconitine induced PVT 28.8 +/- 3.4 min after development of regular monomorphic ventricular tachycardias (MVT) in all 18 preparations. Application of 5 and 10 mM Mg2+ restored aconitine-induced PVT to sinus rhythm after 26.8 +/- 3.4 min (n = 9), but < 3 mM Mg2+ was not effective in restoring of sinus rhythm. Increased Mg2+ concentrations < or = 5 mM in the coronary perfusate prevented development of PVT by aconitine. Intracoronary application of 10 microM tetrodotoxin (TTX) also restored aconitine-induced PVT to sinus rhythm after 3.2 +/- 0.8 min (n = 4). Although applications of 50 microM lidocaine, 10 microM flecainide, or 1 microM verapamil could change PVT to MVT, they were not effective in restoring sinus rhythm. In Purkinje-muscle preparations, spontaneous action potentials (AP) from slow diastolic depolarization appeared after aconitine at the maximum diastolic potential of -75.0 +/- 3.7 mV in Purkinje fibers and were conducted to ventricular muscles (n = 5). Spontaneous activity gradually increased in rate and then developed triggered activity arising from early after depolarization (EAD). EAD induced by aconitine always appeared first in Purkinje fibers and later in muscle fibers. Once triggered activities started from EAD, rate, rhythm and amplitudes of APs became fast and variable.(ABSTRACT TRUNCATED AT 250 WORDS)
Adaniya
H
H
Department of Cardiovascular Diseases, Tokyo Medical and Dental University, Japan.
Hayami
H
H
Hiraoka
M
M
Sawanobori
T
T
D000157:Aconitine / Q000633:toxicity*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use; D004594:Electrophysiology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism; D066298:In Vitro Techniques; D008274:Magnesium / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008839:Microelectrodes; D011690:Purkinje Fibers / Q000187:drug effects* / Q000378:metabolism; D011817:Rabbits; D017180:Tachycardia, Ventricular / Q000139:chemically induced / Q000188:drug therapy*; D013779:Tetrodotoxin / Q000494:pharmacology / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D013779:Tetrodotoxin; D008274:Magnesium; D000157:Aconitine